Handok to introduce calfactant, acute respiratory distress syndrome treatment

Published: 2008-01-09 06:56:00

Updated: 2008-01-09 06:56:00

Handok Pharm says it signed a licensing agreement with the US-based Pneuma Partners to distribute calfactant (trade name: Infasurf), a medication used to treat respiratory distress syndrome (RDS), a lung condition that can occur in prematurely born infants whose lungs have not completely develope...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK